A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

Официальное название

A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.

Обзор

This is a three-part Phase 2a study. The aim of Part A is to assess the safety and tolerability and preliminary antidepressant efficacy in patients with MDD who are not currently on an antidepressant therapy. The aim of Part B is to assess the antidepressant efficacy, safety and tolerability in patients with MDD who are partial responders while on a current and adequate single SSRI or SNRI treatment. Part C aims to replicate the monotherapy findings of Part A, but with a lower control group dose.

Вмешательства

• Препарат GM-2505
  IV

Первичные конечные точки

• Safety and Tolerability (Part A, B, and C) [Срок оценки: 99 Days]
• MADRS Score (Part B and C) [Срок оценки: 29 Days]

Вторичные конечные точки (4)

• MADRS-SIGMA total score (Part A) [Срок оценки: Days 14 and 29]
• MADRS-SIGMA total score (Part B and C) [Срок оценки: All additional timepoints]
• MADRS-SIGMA total score (Part B and C) [Срок оценки: Days 14, 29, 43, 71, and 99]
• PK of GM-2505 (Part C) [Срок оценки: Day 16]

Критерии участия

Критерии включения

• Patients are male or female, of any ethnic origin.
• Patients are aged between 18 to 65 years, inclusive.
• Patients meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for recurrent MDD without psychotic features, as assessed with the Mini-International Neuropsychiatric Interview (MINI) at Screening.
• Current moderate to severe MDD diagnosis confirmed with a MADRS-SIGMA
• Concomitant depression therapy:

• (Part A) Patients need to be stable and must not have taken any SSRI or SNRI for at least 6 weeks prior to Screening and must be willing to avoid starting a new pharmacological treatment for MDD until the end of the study procedures and assessments. Discontinuing current treatment is not allowed if done for the purposes of achieving eligibility for this study.
• (Part B) Patients need to be on stable treatment with any SSRI or SNRI for at least 6 weeks prior to screening and must be willing to remain on the SSRI or SNRI for the duration of the trial
• Patients receiving any form of psychotherapy or counselling must have been receiving therapy at Screening and must be willing to remain in therapy until the end of the study procedures and assessments.

Критерии исключения

• Patient has current or past primary DSM-5 diagnosis of a psychotic disorder or MDD with psychotic features, bipolar, or related disorders. A current diagnosis of PTSD, complex PTSD and borderline personality disorder are exclusionary. Other psychiatric disorders besides MDD should not be the primary disorder.
• In first degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder.
• Current or prior (six weeks before Screening) use of any SSRI/SNRI medication (Part A only).
• Current or prior (five weeks before Screening) use of any monoamine oxidase inhibitor (\[MAO-I\]; including phenelzine, tranylcypromine, isocarboxazid, iproniazid, selegiline, rasagiline, the reversible MAO-I moclobemide and the antibiotic linezolid).or any tricyclic antidepressant

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Великобритания · 1 центр

• MAC Clinical Research — Manchester

Идентификаторы

NCT: NCT06236880 · GM-2505-201 · 2023-000846-40 · M26-286

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗